Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hydroxychloroquine's effect on arteries in APS studied, but trial cut short

NCT ID NCT02595346

Terminated Disease control Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether hydroxychloroquine (Plaquenil) could improve artery function in people with antiphospholipid syndrome (APS), a condition that raises the risk of blood clots. Researchers planned to give either hydroxychloroquine or a placebo to 25 participants and measure changes in blood vessel dilation. However, the trial was terminated early, so the results are limited and not conclusive.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
hydroxychloroquine (also known as Plaquenil)
What this could lead to
If it worked, this could point toward a way to improve blood vessel health and reduce clotting risk in people with antiphospholipid syndrome.
What could go wrong
The trial was terminated early and very small (25 people), so results are limited. Hydroxychloroquine can cause side effects like vision problems or heart issues in some people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME (APS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

antiphospholipid syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTIPHOSPHOLIPID SYNDROME (APS)

Contacts and locations

Locations

  • Rouen University Hospital

    Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.